Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Measurable Residual Disease Testing

Measurable residual disease (MRD) testing measures the amount of cancer cells that are present in blood or bone marrow at the time the sample was collected.

Blood Testing

Regular blood testing for those with CLL and SLL is an important part of managing the disease, as it can provide valuable insights into your overall health.

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL / SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity and, in some cases, normal metabolic activity on PET-CT scans, several patients had persistently enlarged lymph nodes.

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with Undetectable Measurable Residual Disease (MRD) After Treatment with Ibrutinib Plus Venetoclax

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who achieved undetectable measurable (or minimal) residual disease (uMRD) after fixed-duration ibrutinib + venetoclax treatment continue to have excellent outcomes four years after stopping initial therapy. The results of this study suggest that if patients achieve uMRD remission, it is safe to stop treatment.

ASH 2021: Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial

At the 2021 annual meeting of the American Society of Hematology, CLL Society’s Medical Advisory Board Co-Chair Dr. Alex Danilov interviewed Dr. Arnon P. Kater, the lead author of this article and Chair of the Dutch CLL society, to discuss the evolving results of the Murano trial four years later. Please enjoy this interview and article about very hopeful treatment.

Didn't find what you where looking for?

Try our advanced search page!